Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 14/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212356 | 0.90 | PTGER1 (0.53) | PTGER1RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL3227357 | 0.84 | PTGER1 (0.61) | PTGER1 | |
| SCHEMBL3203406 | 0.84 | PTGER1 (0.59) | PTGER1 | |
| SCHEMBL13424616 | 0.82 | KMT2A (0.48) | PTGER1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3221478 | 0.81 | KMT2A (0.47) | PTGER1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3211879 | 0.80 | PTGER1 (0.53) | PTGER1 | |
| SCHEMBL3218995 | 0.80 | PTGER1 (0.57) | PTGER1 | |
| SCHEMBL3213457 | 0.79 | PTGER1 (0.68) | PTGER1 | |
| SCHEMBL3212334 | 0.79 | PTGER1 (0.65) | PTGER1 | |
| SCHEMBL3223821 | 0.76 | PTGER1 (0.47) | PTGER1RAB9ASMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | claimed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| WO-2008098978-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | PTGER1, PTGER2, PTGER4 | PTGER1 1/4885RAB9A 4419/4885NPC1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.